Companies › ReacX Pharmaceuticals
1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 3; Psychiatry; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nalmefene Mu opioid receptor antagonist; Delta opioid receptor antagonist; Kappa opioid receptor partial agonist | OPRM1, OPRD1, OPRK1 | Phase 1 | Opioid Abuse and Addiction; Behavioural Addiction | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07325279 | Nalmefene | Phase 1 | Opioid Abuse and Addiction | Psychiatry | Dec 2026 |
| NCT05540288 | Nalmefene | Phase 3 | Behavioural Addiction | Psychiatry | Jul 2027 |
Trevi Therapeutics Currax Pharmaceuticals AgelessRx Akyso Therapeutics Adneuris Therapeutics Alkermes Boulder Care Inventage Lab. Shionogi Ensysce Biosciences
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.